TSI Inc. has submitted a Type V Drug Master File (DMF), with the FDA, for the BioTrak® Real-Time Viable Particle Counter. The BIOTRAK particle counter gives total and viable airborne particle counts in real time and incorporates TSI field proven, patented Laser Induced Fluorescence (LIF) technology to determine particle viability. Leveraging multiple channels of fluorescence, the BioTrak Particle Counter provides the best viable discrimination available. It also measures total particles and comes with a collection filter for speciation.

The DMF submission contains information including technology description, scientific references, test methodologies and results, evaluation guidance, operating information, and validation information (IQ/OQ/PQ). Specialized aerosol microbial testing was conducted and performance validated in accordance with USP Validation of Alternative Microbial Methods. The DMF contains information supporting the use of the BioTrak detector which is reviewed by the FDA when referenced in manufacturer’s regulatory submittals.

Darrick Niccum, TSI’s Vice President of Marketing stated, “Excellent discussions were held between TSI and the FDA throughout the DMF submittal process. The submission is another step forward for this innovative technology that provides real-time microbial information and helps customers identify root cause of microbial excursions. Ultimately, this enables safer products, helping our customers save money through process improvements.”

Click here to learn more about the BioTrak Real-Time Viable Particle Counter.